Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection

Journal of Hospital Infection

Volumn 57, Issue 3, 2004, Pages 209-216

  Defez, C ^a,b   Fabbro Peray, P ^a,b   Bouziges, N ^a   Gouby, A ^a   Mahamat, A ^a,b   Daures J P ^a,b   Sotto, Albert ^a,b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Multidrug resistance; Nosocomial infection; Pseudomonas aeruginosa; Risk factors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CIPROFLOXACIN; GLYCOPEPTIDE; IMIDAZOLE DERIVATIVE; IMIPENEM; MACROLIDE; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EXPOSURE; GROUPS BY AGE; HOSPITAL DEPARTMENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION RISK; INTESTINE FLORA; MAJOR CLINICAL STUDY; MUCOSA; MULTIDRUG RESISTANCE; NONHUMAN; NOSE FEEDING; PHENOTYPE; PSEUDOMONAS AERUGINOSA; SURGICAL TECHNIQUE; UNIVERSITY HOSPITAL;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; COMORBIDITY; CROSS INFECTION; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTERAL NUTRITION; FEMALE; FLUOROQUINOLONES; FRANCE; HOSPITALS, UNIVERSITY; HUMANS; INFECTION CONTROL; INTESTINAL MUCOSA; INTUBATION, GASTROINTESTINAL; LACTAMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; URINARY CATHETERIZATION;

EID: 3242795872     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2004.03.022     Document Type: Article

References (35)

1. Livermore D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34 2002 634-640
2. Cohen M.L. Fontaine R.E. Pollard R.A. VonAllmen S.D. Vernon T.M. Gangarosa E.J. An assessment of patient-related economic costs in an outbreak of salmonellosis N Engl J Med 299 1978 459-460
3. Howard D.H. Scott II R.D. Packard R. Jones D. The global impact of drug resistance Clin Infect Dis 36 2003 S4-S10
4. Wood M.J. Moellering Jr. R.C. Microbial resistance: bacteria and more Clin Infect Dis 36 2003 S2-S3
5. Lepoutre A. Réseau d'alerte d'investigation et de surveillance des infections nosocomiales Enquête nationale de prévalence : méthodologie et principaux résultats. Ministère délégué à la santé salle Pierre Laroque 5 2001 2002
6. Alonso A. Campanario E. Martinez J.L. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa Microbiology 145 1999 2857-2862
7. Harris A.D. Samore M.H. Lipsitch M. Kaye K.S. Perencevich E. Carmeli Y. Control group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli Clin Infect Dis 34 2002 1558-1563
8. Harris A.D. Karchmer T.B. Carmeli Y. Samore M.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review Clin Infect Dis 32 2001 1055-1061
9. Kaye K.S. Harris A.D. Gold H. Carmeli Y. Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients Antimicrob Agents Chemother 44 2000 1004-1009
10. CDC definitions for nosocomial infections. Am Rev Respir Dis 1989;139:1058-1059.
11. Ministère de l'emploi et de la solidarité, Secrétariat d'Etat à la santé et à l'action sociale, Comité technique national des infections nosocomiales. 100 recommandations pour la surveillance et la prévention des infections nosocomiales; 1999, Paris.
12. Soussy C.J. Carret G. Cavallo J.D. et al. Antibiogram Committee of the French Microbiology Society. Report 2000-2001 Pathol Biol (Paris) 48 2000 832-871
13. McCabe W. Jackson G. Gram-negative bacteremia Arch Intern Med 110 1962 847-855
14. Hosmer D.W. Lemeshow S. Applied logistic regression Probability and Statistics Series 2002 Wiley New York
15. Harris A.D. Smith D. Johnson J.A. Bradham D.D. Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients Clin Infect Dis 34 2002 340-345
16. Harris A.D. Perencevich E. Roghmann M.C. Morris G. Kaye K.S. Johnson J.A. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients Antimicrob Agents Chemother 46 2002 854-858
17. Jacobson K.L. Cohen S.H. Inciardi J.F. et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms Clin Infect Dis 21 1995 1107-1113
18. Neu H.C. Resistance of Pseudomonas aeruginosa to imipenem Infect Control Hosp Epidemiol 13 1992 7-9
19. Satake S. Yoneyama H. Nakae T. Role of OmpD2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa J Antimicrob Chemother 28 1991 199-207
20. Bonten M.J. Bergmans D.C. Speijer H. Stobberingh E.E. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control Am J Respir Crit Care Med 160 1999 1212-1219
21. Vollaard E.J. Clasener H.A. Colonization resistance Antimicrob Agents Chemother 38 1994 409-414
22. Thuong M. Arvaniti K. Ruimy R. et al. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit J Hosp Infect 53 2003 274-282
23. Andremont A. Consequences of antibiotic therapy to the intestinal ecosystem Ann Fr Anesth Reanim 19 2000 395-402
24. Bert F. Lambert-Zechovsky N. Résistance aux antibiotiques et problèmes thérapeutiques posés par Pseudomonas aeruginosa Press Med 28 1999 451-458
25. Bayer A.S. Hirano L. Yih J. Development of β-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis Antimicrob Agents Chemother 32 1988 231-235
26. Paterson D.L. Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach Clin Infect Dis 34 2002 1564-1567
27. Allardet-Servent A. Bouziges N. Carles-Nurit M.J. Bourg G. Gouby A. Ramuz M. Use of low-frequency-cleavage restriction endonucleases for DNA analysis in epidemiological investigations of nosocomial bacterial infections J Clin Microbiol 27 1989 2057-2061
28. Baddour L.M. Hicks D.V.Tayidi M.M. et al. Risk factor assessment for the acquisition of fluoroquinolone-resistant isolates of Pseudomonas aeruginosa in a community-based hospital Microb Drug Resist 1 1995 219-222
29. Harbarth S. Harris A.D. Carmeli Y. Samore M.H. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli Clin Infect Dis 33 2001 1462-1468
30. Bonten M.J. Slaughter S. Ambergen A.W. et al. The role of 'colonization pressure' in the spread of vancomycin-resistant enterococci Arch Intern Med 158 1998 1127-1132
31. Guillemot D. Carbon C. Balkau B. et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae J Am Med Assoc 279 1998 365-370
32. Schneider S.M. Le Gall P. Girard-Pipau F. et al. Total artificial nutrition is associated with major changes in the fecal flora Eur J Nutr 39 2000 248-255
33. Garrel D. Patenaude J. Nedelec B. et al. Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial Crit Care Med 31 2003 2555-2556
34. Robaux M.A. Dube L. Caillon J. et al. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model J Antimicrob Chemother 47 2001 617-622
35. Summers A.O. Generally overlooked fundamentals of bacterial genetics and ecology Clin Infect Dis 34 Suppl. 3 2002 S85-S92